stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) Operating cash flow
Krystal Biotech, Inc.'s operating cash flow for fiscal 2025 was $200.9M, up 62.7% from $123.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $323.9M. Over the past ten years it has ranged from −$100.6M (fiscal 2022) to $200.9M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. Krystal Biotech, Inc. ranks 15th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $200.9M | 62.75% |
| FY2024 | $123.4M | — |
| FY2023 | −$88.8M | — |
| FY2022 | −$100.6M | — |
| FY2021 | −$47.9M | — |
| FY2020 | −$26.1M | — |
| FY2019 | −$18.7M | — |
| FY2018 | −$9.4M | — |
| FY2017 | −$3.9M | — |
| FY2016 | −$1.3M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $91.2M | 22.01% |
| Jun 2026 | $74.8M | (6.96%) |
| Mar 2026 | $80.4M | 3.71% |
| Dec 2025 | $77.5M | 95.44% |
| 37 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. | $323.9M |
| PTGX Protagonist Therapeutics, Inc. compare | $131.2M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.9M |
| TWST Twist Bioscience Corporation compare | −$53.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$157.0M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| IBRX ImmunityBio, Inc. compare | −$281.1M |
| CYTK Cytokinetics, Incorporated compare | −$572.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on KRYS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement